93 related articles for article (PubMed ID: 12424430)
1. Effect of spironolactone on impaired fibrinolysis of hypertensive patients.
Yalcin AI; Dincer M; Aslan V; Gulbas Z
Kidney Blood Press Res; 2002; 25(4):260-4. PubMed ID: 12424430
[TBL] [Abstract][Full Text] [Related]
2. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.
Sawathiparnich P; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2002 Feb; 87(2):448-52. PubMed ID: 11836266
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.
Sawathiparnich P; Murphey LJ; Kumar S; Vaughan DE; Brown NJ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3867-73. PubMed ID: 12915681
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
[TBL] [Abstract][Full Text] [Related]
7. The effects of thiazide and thiazide-potassium sparing diuretics on fibrinolytic system parameters.
Kaşifoğlu T; Yalçin AU
Anadolu Kardiyol Derg; 2006 Jun; 6(2):143-7. PubMed ID: 16766279
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effect of combined spironolactone and quinapril treatment on thrombosis and hemostasis in 2K1C hypertensive rats.
Gromotowicz-Poplawska A; Stankiewicz A; Mikita J; Aleksiejczuk M; Marcinczyk N; Szemraj J; Chabielska E
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980144
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic system in normotensive subjects and hypertensive patients.
Armas-Hernández MJ; Hernández-Hernández R; Armas-Padilla MC; Sosa-Canache B; Cammarata R; Pacheco B; Guerrero-Pajuelo J; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):177-82. PubMed ID: 17414587
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function.
Ridker PM; Gaboury CL; Conlin PR; Seely EW; Williams GH; Vaughan DE
Circulation; 1993 Jun; 87(6):1969-73. PubMed ID: 8504511
[TBL] [Abstract][Full Text] [Related]
12. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
[TBL] [Abstract][Full Text] [Related]
13. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition.
Brown NJ; Muldowney JA; Vaughan DE
Hypertension; 2006 Mar; 47(3):441-8. PubMed ID: 16432054
[TBL] [Abstract][Full Text] [Related]
14. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
Fogari R; Preti P; Lazzari P; Corradi L; Zoppi A; Fogari E; Mugellini A
Eur J Clin Pharmacol; 2003 Aug; 59(4):271-5. PubMed ID: 12830340
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
16. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Fogari R; Derosa G; Lazzari P; Zoppi A; Fogari E; Rinaldi A; Mugellini A
Am J Hypertens; 2004 Sep; 17(9):823-7. PubMed ID: 15363826
[TBL] [Abstract][Full Text] [Related]
17. Impaired fibrinolysis and insulin resistance in patients with hypertension.
Jeng JR; Sheu WH; Jeng CY; Huang SH; Shieh SM
Am J Hypertens; 1996 May; 9(5):484-90. PubMed ID: 8735180
[TBL] [Abstract][Full Text] [Related]
18. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
20. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
